Zenas BioPharma has launched its initial public offering, raising $225 million. The clinical-stage biopharmaceutical company focuses on developing immunology-based therapies. In the IPO, Zenas issued 13,235,294 shares of common stock at $17 each. Underwriters have a 30-day option to purchase an additional 1,985,294 shares. Trading began on September 13, 2024, on the Nasdaq Global Select Market under the ticker symbol ZBIO.
Cooley LLP advised the underwriters for this IPO. The team was led by lawyers Richard Segal, Denny Won, Div Gupta, and Evan Leitner. Cooley provides legal services in transformative deals and complex regulatory matters with nearly 1,400 lawyers across offices in the United States, Asia, and Europe.